Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

• Completed a streamlined Nasdaq listing through a merger transaction, with a common stock capital structure and no preferred stock or debt
• Delivered positive final Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations
• Independent valuation consulting firm, Destum Partners, valued VT-1953 at approximately $1 billion after a successful pivotal study
• Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through mid 2027, taking it up to pivotal trial interim readouts
• Added a new CTO, SVP of Clinical Development, and Senior Medical Advisor, bringing Big Pharma backgrounds, deep drug-development expertise, and experience across multiple FDA-approved therapies

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vyome Holdings, Inc., (“Vyome”) (Nasdaq: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial results and corporate and clinical milestones following its successful listing on Nasdaq.

This quarter marks Vyome’s first annual reporting period as a listed Nasdaq company. Vyome is a clinical-stage company positioned to accelerate development across immuno-inflammatory and potential orphan indications.

“Vyome is targeting one of the biggest challenges in the world today - inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building our business with a laser focus on shareholder value, whether it’s our capital structure or the development of our assets,” said Krishna Gupta, Chairman of Vyome. “We had a great first fiscal year completion as a public company, thanks to our unique strengths, including expertise in/access to the US-India innovation corridor.”

“This annual reporting marks a defining step forward for Vyome. We executed a highly efficient transition to the public markets, spending less cash than expected in 2025 as a public company and strengthening our organization while advancing our lead program,” noted Venkat Nelabhotla, CEO of Vyome. “The promising final Phase 2 results for VT-1953 reinforce the scientific promise of our immuno-inflammation platform. With our disciplined operations, clean capital structure, and world-class team, we are well-positioned to deliver on the milestones ahead and drive long-term value for both shareholders and patients.”

VT-1953: Highly Encouraging Final Phase 2 Study Readouts

The Company’s lead clinical program, VT-1953, a novel, potential first-in-class topical product targeting symptoms of putrid smell and pain in malignant fungating wounds (“MFW”), which is an inflammatory condition afflicting an estimated one million cancer patients, continued to show strong clinical momentum.

• Final Phase 2 Investigator-Initiated Study data demonstrated a statistically significant reduction in the study’s primary endpoint, malodor (P